产品
编 号：F417795
分子式：C7H7NO2
分子量：137.14
分子式：C7H7NO2
分子量：137.14
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
500mg
160
In-stock
1g
240
In-stock
10g
320
In-stock
结构图
CAS No: 65-45-2
产品详情
生物活性：
Salicylamide is an inhibitor of microsomal UDP-glucuronosyltransferase. Salicylamide is an analgesic and anti-pyretic agent.
体内研究：
Salicylamide administration decreases the levels of radiosulfate in maternal serum and placenta, and impaires the incorporation of radiosulfate into fetal skeletal GAGs. Salicylamide administration results in a decrease in the calcium content of fetal limb bones, but has no significant effect on maternal serum calcium. Salicylamide administration decreases radiosulfate uptake by maternal serum and liver, fetus and placenta--effects being dose-dependent. Differences in radiosulfate uptake by the fetus and placenta over time, induced by salicylamide, are also significant independently of maternal serum levels of radiosulfate.
体外研究：
Treatment with salicylamides leads to the bacterial growth inhibition which correlates with the level of inhibition of sulfate reduction.
Salicylamide is an inhibitor of microsomal UDP-glucuronosyltransferase. Salicylamide is an analgesic and anti-pyretic agent.
体内研究：
Salicylamide administration decreases the levels of radiosulfate in maternal serum and placenta, and impaires the incorporation of radiosulfate into fetal skeletal GAGs. Salicylamide administration results in a decrease in the calcium content of fetal limb bones, but has no significant effect on maternal serum calcium. Salicylamide administration decreases radiosulfate uptake by maternal serum and liver, fetus and placenta--effects being dose-dependent. Differences in radiosulfate uptake by the fetus and placenta over time, induced by salicylamide, are also significant independently of maternal serum levels of radiosulfate.
体外研究：
Treatment with salicylamides leads to the bacterial growth inhibition which correlates with the level of inhibition of sulfate reduction.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备